Stock analysts at StockNews.com initiated coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a "sell" rating on the biopharmaceutical company's stock.
Several other research analysts also recently issued reports on LXRX. Piper Sandler lowered their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Leerink Partnrs downgraded Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Lexicon Pharmaceuticals presently has an average rating of "Hold" and an average price target of $3.67.
Check Out Our Latest Report on LXRX
Lexicon Pharmaceuticals Stock Up 1.0 %
Shares of NASDAQ LXRX opened at $0.36 on Wednesday. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. The company has a market cap of $88.25 million, a price-to-earnings ratio of -0.48 and a beta of 1.04. Lexicon Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $2.83. The stock has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $1.11.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. The firm had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. As a group, analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Lexicon Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in shares of Lexicon Pharmaceuticals by 71.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 13,246 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Lexicon Pharmaceuticals by 2.1% during the 4th quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock worth $552,000 after buying an additional 15,249 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 16,136 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Lexicon Pharmaceuticals by 60.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock worth $48,000 after buying an additional 24,615 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Lexicon Pharmaceuticals by 27.4% during the 4th quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company's stock worth $101,000 after buying an additional 29,319 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
